ClinicalTrials.gg
TerminatedNCT02515669Updated Nov 4, 2020Results posted

Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

A Phase 1/2 interventional study of RO7239361 and Placebo in Muscular Dystrophy (DMD), sponsored by Hoffmann-La Roche. Terminated at 12 sites in 2 countries. Open to male participants aged 5 Years to 10 Years. Per ClinicalTrials.gov, last updated 2020-11-04.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Basic science

Why this study was terminated
A pre-planned futility analysis indicated lack of efficacy in study NCT03039686 and led to discontinuation of both ongoing studies in DMD.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
5 Years to 10 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Muscular Dystrophies with a site in United States — 32 open to participants now, 43 under way, 2 of them phase 3. Muscular Dystrophies · United States.

Enrollment
38th of 80
43 · median 41
Started
2015
with 6 others
Phase 1/2
9 of 127
1 open now
Registered
53rd of 127
by date

Among the 127 studies in Muscular Dystrophies with a site in United States, this one is the 38th largest by enrollment of the 80 interventional ones that give a count, is one of 7 that started in 2015, is one of 9 in phase 1/2, and was the 53rd registered.

Muscular Dystrophies

224 studies on the registry are indexed under Muscular Dystrophies; 48 are open to participants now.

Browse Muscular Dystrophies studies →

Open to participants now

32 of the 127 studies in Muscular Dystrophies with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Muscular Dystrophies studies recruiting now, 14 (37%) set no upper age limit and 15 (39%) stop at 75 or younger; 24 take children under 18; 7 take healthy volunteers.

This study: 5 Years to 10 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Muscular Dystrophies with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and tolerability of RO7239361 in boys with Duchenne Muscular Dystrophy with any genetic mutation.

03

Conditions studied

  • Muscular Dystrophy (DMD)

Browse trials for

04

Who can participate

Ages eligible
5 Years to 10 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with DMD
  • Able to walk without assistance
  • Able to walk up 4 stairs in 8 seconds or less
  • Weigh at least 15 kg
  • Taking for DMD

Exclusion criteria

Exclusion Criteria:

  • \< 55% on echocardiogram, based on central read
  • Any behavior or mental issue that will affect the ability to complete the required study procedures
  • Previously or currently taking medications like androgens or human growth hormone
  • Use of a ventilator during the day
  • Unable to have blood samples collected or receive an injection under the skin
  • Treatment with exon skipping therapies 6 months prior to study start
  • Treatment with ataluren or any drug currently or within 5 half-lives prior to study start
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Active comparator
    RO7239361

    RO7239361 subcutaneous injections on specified days

    Drug: RO7239361

  • Placebo comparator
    Placebo

    Placebo subcutaneous injections on specified days

    Drug: Placebo

Interventions

  • Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.

    Also known as: Anti-Myostatin Adnectin, taldefgrobep alfa

  • DrugPlacebo

    Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.

06

What researchers measure

Primary outcomes

  1. Safety Summary for the 24 Week Double-Blind Phase

    Percentage of participants with fatalities, adverse event (AEs) and serious adverse events (SAEs) up to Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Baseline to Week 24

  2. Safety Summary up to Week 72

    Percentage of participants with fatalities, adverse event (AEs) and serious adverse events (SAEs) up to Week 72. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Baseline to Week 72

Secondary outcomes

  1. Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.

    PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361. No participants received the Panel 2 20mg dose.

    Time frame: Day 1: predose, 3, 6, 72 and 96 hours (h) postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

  2. Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 50 mg QW Dose.

    PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

  3. Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.

    PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW. Results for the Panel 3 50mg QW dose level are represented in Outcome Measure 6. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

  4. Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 50 mg QW Dose.

    PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

  5. Area Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.

    PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW Results for the Panel 3 50mg QW dose level are represented in Outcome Measure 8. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

  6. Area Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 50 mg QW Dose.

    PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

  7. RO7239361 Trough Concentrations

    Trough concentrations of RO7239361 at different dose levels. Panel 1 = 4mg, Panel 2 = 12.5mg and 20mg, Panel 3 = 35mg, Expansion Panels = 35mg and 50mg. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose

  8. Percentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment, Double-Blind Phase

    A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Day 8 through Week 24, baseline and on-study information represented in table.

  9. Percentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment up to Week 72

    A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Double-blind phase data for placebo participants is not included. Placebo participants in each arm moved on to RO7239361 upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Day 8 through Week 72, baseline and on-study information represented in table.

  10. Serum Concentration of Free Myostatin in the Double-Blind Phase

    Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Baseline through Week 24

  11. Percent Inhibition of Free Myostatin in the Double-Blind Phase

    Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Baseline through Week 24

  12. Serum Concentration of Drug-Myostatin Complex in the Double-Blind Phase

    Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Baseline through Week 24

  13. Fold Change From Baseline in Contractile Versus Non-contractile Content for Muscles in the Right Thigh in the Double-Blind Phase

    Ratio of contractile vs non-contractile content is contractile content / non-contractile content. Fold change from baseline of the ratio is defined as the ratio of fold change from baseline of contractile content vs fold change from baseline of non-contractile content. Right thigh measurements. W12 = Week 12, W24 = Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Baseline through Week 24

  14. Change From Baseline in Thigh Muscle Maximal Cross Sectional Area (CSAmax) in the Double-Blind Phase

    Right thigh measurements. W12 = Week 12, W24 = Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Baseline through Week 24

  15. Percentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment, Whole Study

    A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Day 8 through Week 228, baseline and on-study information represented in table.

  16. Serum Concentration of Free Myostatin, Whole Study

    Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Baseline through Week 252

  17. Percent Inhibition of Free Myostatin, Whole Study

    Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Baseline through Week 252

  18. Serum Concentration of Drug-Myostatin Complex, Whole Study

    Participants in the Placebo arm received placebo during the double-blind (DB) period (up to Week 24) and received RO7239361 during the open label (OL) phase. PFS in table row title indicates when study drug was changed from vial to prefilled syringe (PFS). Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

    Time frame: Baseline through Week 252

07

Results

Posted May 8, 2019

Participant flow

Doses for this study are based upon achieving a moderate to high degree of suppression in serum free myostatin at steady-state trough across 3 dose levels. A body weight-tiered, fixed-dose strategy targeting moderate (\>50%), high (\>85%) and near complete (\>95%) suppression of serum free myostatin was used to select the three doses for the study.

24 Week Double-Blind Phase
Participant flow — 24 Week Double-Blind Phase
MilestonePlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Started117619
Completed117619
Not completed0000
228 Week Open-Label Phase
Participant flow — 228 Week Open-Label Phase
MilestonePlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Started09826
Completed0000
Not completed09826
Withdrew: Other0014
Withdrew: Lack of efficacy0010
Withdrew: Subject request to discontinue treatment0023
Withdrew: Administrative reason by sponsor07217
Withdrew: Missing0222

Outcome measures

PrimarySafety Summary for the 24 Week Double-Blind Phase

Percentage of participants with fatalities, adverse event (AEs) and serious adverse events (SAEs) up to Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Safety Summary for the 24 Week Double-Blind Phase
percentage of participantsPlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion RO7239361
Death0000
Adverse Events (AEs)81.871.4100.094.7
AEs leading to study withdrawal0000
Serious Adverse Events (SAE)9.1005.3
Very Severe AEs0000
Severe AEs0000
Related AEs27.314.350.036.8
PrimarySafety Summary up to Week 72

Percentage of participants with fatalities, adverse event (AEs) and serious adverse events (SAEs) up to Week 72. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Baseline to Week 72
Reported as:
Number · percentage of participants
Safety Summary up to Week 72
percentage of participantsPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Death000
Adverse Events (AEs)100.0100.096.2
AEs leading to study withdrawal000
Serious Adverse Events (SAE)025.07.7
Very Severe AEs000
Severe AEs025.03.8
Related AEs77.862.550.0
SecondaryMaximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.

PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361. No participants received the Panel 2 20mg dose.

Time frame:
Day 1: predose, 3, 6, 72 and 96 hours (h) postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Reported as:
Geometric mean · ng/ml
Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.
ng/mlPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.3217 ± 15.88490 ± 21.524242 ± 26.3
SecondaryMaximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 50 mg QW Dose.

PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Reported as:
Geometric mean · ng/mL
Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 50 mg QW Dose.
ng/mLPanel 3 and Expansion Panel RO7239361
Maximum Observed Serum Concentrations (Cmax) of RO7239361 at Steady State for 50 mg QW Dose.23297 ± NA
SecondaryTime of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.

PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW. Results for the Panel 3 50mg QW dose level are represented in Outcome Measure 6. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Reported as:
Median · hour
Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.
hourPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.28 (12 to 48)24 (11 to 47)30 (11 to 65)
SecondaryTime of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 50 mg QW Dose.

PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Reported as:
Median · hour
Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 50 mg QW Dose.
hourPanel 3 and Expansion Panel RO7239361
Time of Maximum Observed Serum Concentrations (Tmax) of RO7239361 at Steady State for 50 mg QW Dose.44 (NA to NA)
SecondaryArea Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.

PK parameter estimates at steady state. Steady state was achieved following approximately 12 weeks QW administration. Panel: 1 = 4mg QW, 2 = 12.5mg QW, 3 = 35mg QW Results for the Panel 3 50mg QW dose level are represented in Outcome Measure 8. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Reported as:
Geometric mean · ng•day/mL
Area Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.
ng•day/mLPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Area Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 4 mg QW, 12.5 mg QW and 35 mg QW Doses.18676 ± 2351461 ± 18150609 ± 24
SecondaryArea Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 50 mg QW Dose.

PK parameter estimates at steady state following approximately 12 weeks QW administration. Panel 3 = 50 mg QW Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Reported as:
Geometric mean · ng•day/mL
Area Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 50 mg QW Dose.
ng•day/mLPanel 3 and Expansion Panel RO7239361
Area Under the Concentration-Time Curve From Time Zero to Time of Next Dosing (AUCtau) of RO7239361 at Steady State for 50 mg QW Dose.151000 ± NA
SecondaryRO7239361 Trough Concentrations

Trough concentrations of RO7239361 at different dose levels. Panel 1 = 4mg, Panel 2 = 12.5mg and 20mg, Panel 3 = 35mg, Expansion Panels = 35mg and 50mg. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Day 1: predose, 3, 6, 72 and 96 h postdose; Days 8, 15 and 22: predose; Day 29: predose and 96 h postdose; Weeks 12 and 24: predose
Reported as:
Geometric mean · ng/mL
RO7239361 Trough Concentrations
ng/mLPanel 1 RO7239361Panel 2 RO7239361 12.5mgPanel 2 RO7239361 20mgPanel 3 RO7239361 35mgExpansion Panel RO7239361 35mgExpansion Panel RO7239361 50mg
Day 1825.343 ± 232115.951 ± 20—6559.364 ± 266017.978 ± 235020.000 ± NA
Day 151258.746 ± 353697.590 ± 20—9957.352 ± 349944.183 ± 249980.000 ± NA
Day 221640.052 ± 154220.280 ± 32—12383.747 ± 3013215.188 ± 24NA ± NA
Day 292015.695 ± 325107.668 ± 25—14110.005 ± 3415094.455 ± 19NA ± NA
Day 842179.385 ± 266484.502 ± 19—19332.421 ± 2018789.382 ± 1827800.000 ± NA
Day 1682438.595 ± 166100.315 ± 256340.000 ± NA19923.182 ± 4112580.299 ± 4126200.000 ± NA
SecondaryPercentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment, Double-Blind Phase

A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Day 8 through Week 24, baseline and on-study information represented in table.
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment, Double-Blind Phase
percentage of participantsPlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Baseline (BL): ADA Positive0000
BL: ADA Negative071.4100.089.5
BL: Missing100.028.6010.5
On-treatment: ADA Positive0000
On-treatment: Persistent Positive0000
On-treatment: Only last sample Positive0000
On-treatment: Other Positive0000
On-treatment: ADA Negative0100.0100.0100.0
On-treatment: ADA Negative, BL Positive, No Boost0000
On-treatment: Missing100.0000
SecondaryPercentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment up to Week 72

A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Double-blind phase data for placebo participants is not included. Placebo participants in each arm moved on to RO7239361 upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Day 8 through Week 72, baseline and on-study information represented in table.
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment up to Week 72
percentage of participantsPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Baseline (BL): ADA Positive000
BL: ADA Negative77.887.588.5
BL: Missing22.212.511.5
On-treatment: ADA Positive003.8
On-treatment: Persistent Positive000
On-treatment: Only last sample Positive003.8
On-treatment: Other Positive000
On-treatment: ADA Negative100.0100.096.2
On-treatment: ADA Negative, BL Positive, No Boost000
On-treatment: Missing000
SecondarySerum Concentration of Free Myostatin in the Double-Blind Phase

Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Baseline through Week 24
Reported as:
Mean · pg/mL
Serum Concentration of Free Myostatin in the Double-Blind Phase
pg/mLPlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Baseline1405.1 ± 809.57815.3 ± 155.141391.3 ± 1084.971121.8 ± 526.45
Day 41356.6 ± 641.27421.4 ± 70.60321.3 ± 165.9158.3 ± 33.20
Day 51438.2 ± 809.18446.6 ± 108.81357.8 ± 166.2766.1 ± 39.07
Day 81014.2 ± 549.26522.7 ± 131.51479.2 ± 319.13206.8 ± 419.21
Day 151266.9 ± 611.27478.4 ± 111.44280.8 ± 148.5354.8 ± 61.85
Day 221317.1 ± 728.48382.4 ± 82.58284.8 ± 324.1635.3 ± 51.45
Day 291214.0 ± 676.80372.3 ± 79.97179.0 ± 137.3924.8 ± 27.24
Day 331141.4 ± 606.99291.1 ± 77.55115.7 ± 84.4924.3 ± 30.64
Week 121366.5 ± 631.28307.8 ± 97.84110.8 ± 49.8016.2 ± 11.60
Week 241194.0 ± 599.59297.1 ± 74.62160.8 ± 122.7523.4 ± 25.34
SecondaryPercent Inhibition of Free Myostatin in the Double-Blind Phase

Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Baseline through Week 24
Reported as:
Mean · percentage inhibition
Percent Inhibition of Free Myostatin in the Double-Blind Phase
percentage inhibitionPlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Day 40.595 ± 23.695249.689 ± 11.739473.533 ± 9.863795.334 ± 2.4477
Day 53.114 ± 20.339546.506 ± 9.091769.700 ± 10.341194.545 ± 2.7608
Day 823.917 ± 31.137838.411 ± 7.032062.524 ± 9.707484.797 ± 22.1958
Day 155.744 ± 18.619040.763 ± 10.007177.090 ± 6.293996.488 ± 1.9665
Day 225.561 ± 11.742551.836 ± 9.348881.693 ± 5.739297.927 ± 1.1259
Day 2912.599 ± 16.159152.926 ± 6.600186.894 ± 2.959098.202 ± 1.4590
Day 3315.662 ± 17.364061.796 ± 4.576091.557 ± 2.644497.042 ± 5.4443
Week 125.289 ± 15.508260.254 ± 9.428392.454 ± 1.724398.415 ± 1.2882
Week 249.910 ± 17.810963.790 ± 5.703188.392 ± 5.166997.921 ± 2.2143
SecondarySerum Concentration of Drug-Myostatin Complex in the Double-Blind Phase

Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Baseline through Week 24
Reported as:
Mean · ng/mL
Serum Concentration of Drug-Myostatin Complex in the Double-Blind Phase
ng/mLPlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Day 41.178 ± 1.88335.070 ± 0.945612.606 ± 5.762314.696 ± 5.7926
Day 52.119 ± 2.98265.845 ± 2.572514.856 ± 7.613117.308 ± 7.5955
Day 84.924 ± 12.99757.041 ± 2.347019.906 ± 9.866421.609 ± 11.0880
Day 150.613 ± 0.210214.067 ± 7.109629.229 ± 10.492945.289 ± 18.7600
Day 221.326 ± 1.341011.985 ± 4.824336.811 ± 26.856052.841 ± 21.5542
Day 291.593 ± 3.100715.735 ± 4.201043.236 ± 34.030067.255 ± 27.9376
Day 331.157 ± 1.003618.542 ± 3.987446.279 ± 24.145777.142 ± 32.4153
Week 127.082 ± 15.228928.556 ± 22.789079.555 ± 17.212688.402 ± 29.8080
Week 243.589 ± 7.810825.997 ± 6.438483.262 ± 64.2281101.406 ± 45.4197
SecondaryFold Change From Baseline in Contractile Versus Non-contractile Content for Muscles in the Right Thigh in the Double-Blind Phase

Ratio of contractile vs non-contractile content is contractile content / non-contractile content. Fold change from baseline of the ratio is defined as the ratio of fold change from baseline of contractile content vs fold change from baseline of non-contractile content. Right thigh measurements. W12 = Week 12, W24 = Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Baseline through Week 24
Reported as:
Mean · Fold Change
Fold Change From Baseline in Contractile Versus Non-contractile Content for Muscles in the Right Thigh in the Double-Blind Phase
Fold ChangePlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 RO7239361Expansion Panel RO7239361
W12: ADDUCTOR LONGUS1.04 ± 0.2910.95 ± 0.0881.16 ± 0.3302.27 ± 1.1222.36 ± 0.875
W12: ADDUCTOR MAGNUS0.69 ± 0.1040.88 ± 0.2831.12 ± 0.2810.93 ± 0.2551.04 ± 0.101
W12: BICEPS FEMORIS LONG0.78 ± 0.2210.94 ± 0.3041.57 ± 0.5561.10 ± 0.2801.26 ± 0.237
W12: BICEPS FEMORIS SHORT0.92 ± 0.2692.77 ± 1.1442.03 ± 1.5640.79 ± 0.1621.31 ± 0.301
W12: GRACILIS1.13 ± 0.3187.57 ± 5.3720.98 ± 0.1763.41 ± 2.4745.42 ± 3.871
W12:RECTUS FEMORIS0.74 ± 0.1850.55 ± 0.1344.49 ± 2.7290.99 ± 0.3452.02 ± 0.764
W12: SARTORIUS1.78 ± 0.7710.69 ± 0.3071.04 ± 0.4430.90 ± 0.3962.00 ± 0.683
W12: SEMIMEMBRANOSUS0.82 ± 0.2300.82 ± 0.2841.47 ± 0.7770.86 ± 0.2761.31 ± 0.194
W12: SEMITENDINOSUS0.78 ± 0.2622.95 ± 1.0161.31 ± 0.2601.42 ± 0.3171.17 ± 0.160
W12: VASTUS INTERMEDIUS2.59 ± 1.7491.11 ± 0.2920.62 ± 0.2580.86 ± 0.1571.64 ± 0.377
W12: VASTUS LATERALIS0.66 ± 0.1600.89 ± 0.2721.10 ± 0.3331.78 ± 0.4551.70 ± 0.334
W12: VASTUS MEDIALIS1.08 ± 0.2691.26 ± 0.1122.97 ± 1.9810.85 ± 0.2805.96 ± 3.376
W24: ADDUCTOR LONGUS0.81 ± 0.2901.14 ± 0.2691.11 ± 0.4711.36 ± 0.7182.41 ± 0.813
W24: ADDUCTOR MAGNUS0.66 ± 0.1120.94 ± 0.2960.59 ± 0.1441.61 ± 0.6971.14 ± 0.146
W24: BICEPS FEMORIS LONG1.07 ± 0.5111.13 ± 0.3151.00 ± 0.3491.29 ± 0.2382.10 ± 1.044
W24: BICEPS FEMORIS SHORT0.91 ± 0.1952.24 ± 1.0272.15 ± 1.0031.24 ± 0.4112.02 ± 0.416
W24: GRACILIS1.43 ± 0.6863.03 ± 2.5641.37 ± 0.4651.45 ± 0.7485.17 ± 3.540
W24:RECTUS FEMORIS0.94 ± 0.2560.84 ± 0.2207.43 ± 6.2160.80 ± 0.2623.01 ± 1.612
W24: SARTORIUS1.90 ± 0.8720.73 ± 0.2070.78 ± 0.3753.24 ± 1.8502.45 ± 0.842
W24: SEMIMEMBRANOSUS0.66 ± 0.1260.90 ± 0.3610.72 ± 0.1570.94 ± 0.2501.39 ± 0.256
W24: SEMITENDINOSUS0.56 ± 0.1191.59 ± 0.5201.43 ± 0.5241.04 ± 0.2541.22 ± 0.221
W24: VASTUS INTERMEDIUS0.95 ± 0.4121.47 ± 0.4460.63 ± 0.3550.96 ± 0.0951.47 ± 0.318
W24: VASTUS LATERALIS0.78 ± 0.1591.88 ± 0.9051.45 ± 0.5961.43 ± 0.2562.03 ± 0.484
W24: VASTUS MEDIALIS2.14 ± 0.8895.16 ± 3.5806.01 ± 5.4781.29 ± 0.4743.50 ± 1.390
SecondaryChange From Baseline in Thigh Muscle Maximal Cross Sectional Area (CSAmax) in the Double-Blind Phase

Right thigh measurements. W12 = Week 12, W24 = Week 24. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Baseline through Week 24
Reported as:
Mean · Percentage Change
Change From Baseline in Thigh Muscle Maximal Cross Sectional Area (CSAmax) in the Double-Blind Phase
Percentage ChangePlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3RO7239361Expansion Panel RO7239361
W12: ADDUCTOR LONGUS7.29 ± 16.5598.31 ± 11.7675.85 ± 11.07414.61 ± 9.75529.98 ± 8.530
W12: ADDUCTOR MAGNUS31.01 ± 24.70824.12 ± 11.804-3.73 ± 29.03753.20 ± 25.3284.01 ± 54.787
W12: BICEPS FEMORIS LONG34.24 ± 18.32833.43 ± 35.00916.72 ± 17.80619.22 ± 9.80223.93 ± 11.289
W12: BICEPS FEMORIS SHORT14.10 ± 7.7247.45 ± 11.5922.69 ± 13.73318.68 ± 7.4799.84 ± 3.882
W12: GRACILIS20.14 ± 15.48943.00 ± 28.53915.28 ± 8.69327.02 ± 5.68623.22 ± 5.440
W12:RECTUS FEMORIS-7.86 ± 14.39110.33 ± 11.927-3.56 ± 14.17534.91 ± 6.03716.01 ± 9.888
W12: SARTORIUS11.26 ± 6.5846.59 ± 11.952-0.85 ± 6.38310.81 ± 11.01718.20 ± 5.519
W12: SEMIMEMBRANOSUS39.11 ± 15.04132.57 ± 19.13316.56 ± 19.99846.70 ± 16.48031.01 ± 10.564
W12: SEMITENDINOSUS25.03 ± 9.409-1.24 ± 10.97333.00 ± 26.73036.69 ± 14.80240.10 ± 10.180
W12: VASTUS INTERMEDIUS10.47 ± 12.16023.35 ± 12.704-52.03 ± 71.421-0.81 ± 19.35310.44 ± 7.344
W12: VASTUS LATERALIS31.47 ± 39.34338.32 ± 19.57014.08 ± 27.90257.86 ± 34.02622.73 ± 15.138
W12: VASTUS MEDIALIS-17.89 ± 19.35815.65 ± 8.463-11.60 ± 15.84921.14 ± 9.74617.89 ± 6.788
W24: ADDUCTOR LONGUS11.69 ± 15.62623.41 ± 13.19912.81 ± 16.39317.15 ± 15.48444.12 ± 13.323
W24: ADDUCTOR MAGNUS34.17 ± 24.91821.90 ± 12.345-6.71 ± 37.31145.05 ± 27.5204.41 ± 52.393
W24: BICEPS FEMORIS LONG39.21 ± 19.76042.84 ± 22.086-5.32 ± 29.14033.70 ± 12.07331.33 ± 13.370
W24: BICEPS FEMORIS SHORT20.09 ± 9.81811.83 ± 13.013-0.44 ± 16.18330.01 ± 13.49418.60 ± 5.394
W24: GRACILIS8.14 ± 7.14818.72 ± 16.75711.21 ± 5.46148.95 ± 17.06440.15 ± 8.382
W24:RECTUS FEMORIS8.97 ± 10.2147.68 ± 13.082-10.01 ± 16.12155.65 ± 27.53538.40 ± 14.293
W24: SARTORIUS10.75 ± 7.1360.81 ± 8.143-14.18 ± 9.48116.63 ± 4.47625.51 ± 6.404
W24: SEMIMEMBRANOSUS45.83 ± 14.89630.01 ± 18.631-11.48 ± 24.46861.03 ± 25.52449.49 ± 12.011
W24: SEMITENDINOSUS32.00 ± 16.10236.17 ± 23.28524.16 ± 23.40373.68 ± 17.59462.55 ± 11.073
W24: VASTUS INTERMEDIUS14.86 ± 15.07243.01 ± 11.506-68.05 ± 86.36241.63 ± 34.92622.55 ± 8.284
W24: VASTUS LATERALIS12.95 ± 35.46547.79 ± 26.17832.64 ± 30.13645.41 ± 43.77446.87 ± 20.919
W24: VASTUS MEDIALIS-9.09 ± 11.8569.82 ± 6.965-13.74 ± 29.66410.46 ± 12.09323.94 ± 11.321
SecondaryPercentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment, Whole Study

A positive ADA sample is defined as one in which the presence of detectable ADAs is confirmed to be specific to RO7239361. A participant is considered as ADA positive if, after initiation of treatment, they have an ADA positive relative to baseline sample. Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Day 8 through Week 228, baseline and on-study information represented in table.
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Anti-RO7239361 Antibodies (ADA) Assessment, Whole Study
percentage of participantsPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Baseline (BL): ADA Positive000
BL: ADA Negative100.087.592.3
BL: Missing012.57.7
On-treatment: ADA Positive003.8
On-treatment: Persistent Positive000
On-treatment: Only last sample Positive000
On-treatment: Other Positive003.8
On-treatment: ADA Negative100.0100.096.2
On-treatment: ADA Negative, BL Positive, No Boost000
On-treatment: Missing000
SecondarySerum Concentration of Free Myostatin, Whole Study

Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Baseline through Week 252
Reported as:
Mean · pg/mL
Serum Concentration of Free Myostatin, Whole Study
pg/mLPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Baseline986.8 ± 363.691358.4 ± 964.471159.3 ± 601.29
Day 4421.4 ± 70.60321.3 ± 165.9158.3 ± 33.20
Day 5446.6 ± 108.81357.8 ± 166.2766.1 ± 39.07
Day 8522.7 ± 131.51479.2 ± 319.13206.8 ± 419.21
Day 15478.4 ± 111.44280.8 ± 148.5354.8 ± 61.85
Day 22382.4 ± 82.58284.8 ± 324.1635.3 ± 51.45
Day 29372.3 ± 79.97179.0 ± 137.3924.8 ± 27.24
Day 33291.1 ± 77.55115.7 ± 84.4924.3 ± 30.64
Week 12394.0 ± 179.78115.0 ± 62.2318.1 ± 13.37
Week 24357.9 ± 137.56139.1 ± 111.6323.0 ± 23.68
Week 25331.0 ± 116.78154.5 ± 115.2122.8 ± 18.48
Week 36340.3 ± 98.2481.4 ± 36.0021.1 ± 22.03
Week 48401.3 ± 233.7679.0 ± 37.8518.6 ± 12.11
Week 60284.6 ± 96.9290.4 ± 39.3036.3 ± 54.13
Week 72326.8 ± 151.29132.0 ± 146.37205.7 ± 321.58
Week 84534.0 ± 260.3174.2 ± 13.58115.6 ± 146.44
Week 108320.9 ± 222.1084.4 ± 61.1940.2 ± 42.70
Week 132283.5 ± 103.7371.0 ± 40.0240.2 ± 38.26
Week 144—95.2 ± NA—
Week 156208.7 ± 64.5248.9 ± 22.4220.0 ± 0.00
Week 180212.5 ± 146.37——
Week 252—20.0 ± NA—
SecondaryPercent Inhibition of Free Myostatin, Whole Study

Double-blind phase data for placebo participants are not included in this Whole Study outcome measure, but are reported in the outcome measure specific to the double-blind period. At the end of the double-blind period participants in the placebo arm switched to one of the RO7239361 arms upon entering the open label phase. Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Baseline through Week 252
Reported as:
Mean · percentage inhibition
Percent Inhibition of Free Myostatin, Whole Study
percentage inhibitionPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361
Day 449.689 ± 11.739473.533 ± 9.863795.334 ± 2.4477
Day 546.506 ± 9.091769.700 ± 10.341194.545 ± 2.7608
Day 838.411 ± 7.032062.524 ± 9.707484.797 ± 22.1958
Day 1540.763 ± 10.007177.090 ± 6.293996.488 ± 1.9665
Day 2251.836 ± 9.348881.693 ± 5.739297.927 ± 1.1259
Day 2952.926 ± 6.600186.894 ± 2.959098.202 ± 1.4590
Day 3361.796 ± 4.576091.557 ± 2.644497.042 ± 5.4443
Week 1258.934 ± 8.734592.025 ± 2.054898.208 ± 1.5605
Week 2463.199 ± 5.341989.664 ± 5.024598.009 ± 1.8677
Week 2562.446 ± 7.066888.689 ± 4.886897.974 ± 1.8259
Week 3664.103 ± 5.377492.057 ± 2.630098.470 ± 0.8410
Week 4858.161 ± 15.710192.237 ± 3.495298.036 ± 1.4516
Week 6066.280 ± 8.468490.974 ± 2.178097.177 ± 2.8783
Week 7265.956 ± 8.206692.536 ± 2.444579.193 ± 31.9504
Week 8454.990 ± 11.039792.328 ± 5.794589.744 ± 13.0990
Week 10870.498 ± 15.290592.412 ± 3.366295.884 ± 3.5214
Week 13271.129 ± 4.957692.935 ± 3.812196.713 ± 2.4278
Week 144—94.732 ± NA—
Week 15674.712 ± 5.776494.881 ± 1.372698.183 ± 0.8086
Week 18075.374 ± 9.5968——
Week 252—96.283 ± NA—
SecondarySerum Concentration of Drug-Myostatin Complex, Whole Study

Participants in the Placebo arm received placebo during the double-blind (DB) period (up to Week 24) and received RO7239361 during the open label (OL) phase. PFS in table row title indicates when study drug was changed from vial to prefilled syringe (PFS). Participants in Panel 1 received 4 mg RO7239361; participants in Panel 2 received either 12.5 mg (weight between 15 and 45 kg) or 20 mg (weight \>45 kg) RO7239361, and participants in Panel 3 and the Expansion Panel received either 35 mg (weight between 15 and 45 kg) or 50 mg (weight \>45 kg) RO7239361.

Time frame:
Baseline through Week 252
Reported as:
Mean · ng/mL
Serum Concentration of Drug-Myostatin Complex, Whole Study
ng/mLPlacebo, Then RO7239361Panel 1 RO7239361 Whole StudyPanel 2 RO7239361 Whole StudyPanel 3 and Expansion Panel RO7239361 Whole Study
Day 41.178 ± 1.88335.070 ± 0.945612.606 ± 5.762314.696 ± 5.7926
Day 52.119 ± 2.98265.845 ± 2.572514.856 ± 7.613117.308 ± 7.5955
Day 84.924 ± 12.99757.041 ± 2.347019.906 ± 9.866421.609 ± 11.0880
Day 150.613 ± 0.210214.067 ± 7.109629.229 ± 10.492945.289 ± 18.7600
Day 221.326 ± 1.341011.985 ± 4.824336.811 ± 26.856052.841 ± 21.5542
Day 291.593 ± 3.100715.735 ± 4.201043.236 ± 34.030067.255 ± 27.9376
Day 331.157 ± 1.003618.542 ± 3.987446.279 ± 24.145777.142 ± 32.4153
Week 127.082 ± 15.228928.556 ± 22.789079.555 ± 17.212688.402 ± 29.8080
Week 24 (end of DB period)3.589 ± 7.810825.997 ± 6.438483.262 ± 64.2281101.406 ± 45.4197
Week 25 (Week 1 OL)3.186 ± 6.973431.963 ± 8.024077.926 ± 56.9987102.211 ± 40.2284
Week 36 (Week 12 OL)95.788 ± 88.152122.584 ± 8.683957.164 ± 25.8284101.234 ± 42.0902
Week 48 (Week 24 OL)90.593 ± 73.710227.461 ± 7.2306—103.657 ± 45.8802
Week 60 (Week 36 OL)63.358 ± 37.559141.779 ± 34.240789.712 ± 38.921467.163 ± 8.4904
Week 72 (Week 48 OL)92.086 ± 68.522226.740 ± 3.02560.550 ± NA102.025 ± 31.4717
Week 84 (Week 60 OL)146.950 ± 131.370627.110 ± 3.2527—117.719 ± 41.1143
Week 108 (Week 84 OL)122.610 ± 87.191136.014 ± 10.933866.020 ± 7.2878114.806 ± 32.7432
Week 132 (Week 108 OL)95.811 ± 48.144032.133 ± 8.284875.040 ± 14.3015107.378 ± 37.8814
Week 144 (Week 120 OL)—25.600 ± NA——
Week 156 (Week 132 OL)95.529 ± 48.006530.186 ± 7.005369.325 ± 17.7064108.100 ± 35.5833
Week 156 (Week 132 OL: Day 1 PFS)64.400 ± 0.5657———
Week 156 (Week 132 OL: Week 12 PFS)152.000 ± NA——125.583 ± 44.4144
Week 168 (Week 144 OL: Day 1 PFS)105.700 ± 54.5772—70.100 ± 25.1213122.633 ± 91.2542
Week 168 (Week 144 OL: Day 8 PFS)———119.000 ± NA
Week 168 (Week 144 OL: Week 12 PFS)——94.900 ± NA—
Week 180 (Week 156 OL)45.933 ± 28.316125.589 ± 12.2478103.300 ± 16.5463—
Week 180 (Week 156 OL: Week 12 PFS)—62.600 ± NA——
Week 192 (Week 168 OL: Day 1 PFS)—18.000 ± NA——
Week 192 (Week 168 OL: Day 45 PFS)—80.400 ± NA——
Week 252 (Week 228 OL)96.770 ± 61.608452.680 ± 20.861987.900 ± 38.5763106.071 ± 48.6434

Adverse events

Collected over Baseline up to Week 252. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Double-Blind0/11 (0%)1/11 (9.1%)9/11 (81.8%)
Panel 1 RO7239361 Double-Blind0/7 (0%)0/7 (0%)5/7 (71.4%)
Panel 2 RO7239361 Double-Blind0/6 (0%)0/6 (0%)6/6 (100%)
Panel 3 and Expansion Panel RO7239361 Double-Blind0/19 (0%)1/19 (5.3%)17/19 (89.5%)
Panel 1 RO7239361 Open-Label0/9 (0%)1/9 (11.1%)9/9 (100%)
Panel 2 RO7239361 Open-Label0/8 (0%)2/8 (25%)6/8 (75%)
Panel 3 and Expansion Panel RO7239361 Open-Label0/26 (0%)1/26 (3.8%)24/26 (92.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo Double-BlindPanel 1 RO7239361 Double-BlindPanel 2 RO7239361 Double-BlindPanel 3 and Expansion Panel RO7239361 Double-BlindPanel 1 RO7239361 Open-LabelPanel 2 RO7239361 Open-LabelPanel 3 and Expansion Panel RO7239361 Open-Label
INFLUENZAInfections and infestations0/110/70/60/190/91/80/26
RHABDOMYOLYSISMusculoskeletal and connective tissue disorders0/110/70/60/190/91/80/26
CONVERSION DISORDERPsychiatric disorders0/110/70/60/190/91/80/26
APPENDICITIS PERFORATEDInfections and infestations0/110/70/60/191/90/80/26
SKULL FRACTUREInjury, poisoning and procedural complications1/110/70/60/190/90/80/26
SPINAL COMPRESSION FRACTUREInjury, poisoning and procedural complications0/110/70/61/190/90/80/26
FEMUR FRACTUREInjury, poisoning and procedural complications0/110/70/60/190/90/81/26
Most frequent other events
Showing 10 of 149
Most frequent other events
EventPlacebo Double-BlindPanel 1 RO7239361 Double-BlindPanel 2 RO7239361 Double-BlindPanel 3 and Expansion Panel RO7239361 Double-BlindPanel 1 RO7239361 Open-LabelPanel 2 RO7239361 Open-LabelPanel 3 and Expansion Panel RO7239361 Open-Label
FALLInjury, poisoning and procedural complications0/111/70/61/197/90/86/26
INJECTION SITE IRRITATIONGeneral disorders0/111/70/60/195/90/80/26
COUGHRespiratory, thoracic and mediastinal disorders2/110/70/62/191/94/87/26
RASHSkin and subcutaneous tissue disorders0/110/73/61/190/90/82/26
VOMITINGGastrointestinal disorders1/111/70/64/194/91/88/26
INJECTION SITE ERYTHEMAGeneral disorders0/110/70/61/194/90/88/26
NASOPHARYNGITISInfections and infestations1/111/71/64/194/91/87/26
CONTUSIONInjury, poisoning and procedural complications1/111/70/60/194/90/84/26
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/110/72/64/190/91/811/26
HEADACHENervous system disorders2/112/71/67/192/90/89/26

Baseline characteristics

Doses tested in this study were based upon achieving and maintaining moderate (\> 50% suppression), high (\> 85%), and near complete (\> 95%) suppression of serum free myostatin levels for Panels 1, 2, and 3 and Expansion Panel, respectively. Panel 3 was expanded after at least 2 weeks of dosing had been complete by at least 6 participants.

Age, Continuous
Age, Continuous(Years)PlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361Total
Mean8.8 ± 1.338.0 ± 2.248.0 ± 1.798.1 ± 1.818.2 ± 1.74
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361Total
Female00000
Male11761943
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361Total
Hispanic or Latino10124
Not Hispanic or Latino9751334
Unknown or Not Reported10045
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboPanel 1 RO7239361Panel 2 RO7239361Panel 3 and Expansion Panel RO7239361Total
American Indian or Alaska Native01001
Asian20259
Native Hawaiian or Other Pacific Islander00000
Black or African American00101
White9631331
More than one race00000
Unknown or Not Reported00011
08

Study locations

12 sites
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90095-6984, United States
  • Stanford University
    Palo Alto, California 94305, United States
  • University of Florida
    Gainesville, Florida 32607, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30324, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • Saint Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
  • Children'S Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Feb 2018, 26 months.

Results were first posted in May 2019, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2015
First posted
Aug 5, 2015
StartActual
Dec 2, 2015
Primary completionActual
Feb 8, 2018
CompletionActual
Apr 15, 2020
Results first posted
May 8, 2019
Last update
Nov 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02515669
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 5, 2015
Start date
Dec 2, 2015
Primary completion
Feb 8, 2018
Completion
Apr 15, 2020
Results posted
May 8, 2019
Last update
Nov 4, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Taldefgrobep alfa

Start the discussion